Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
2024年8月15日 - 3:30AM
Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a
developmental stage biopharmaceutical company focused on developing
novel formulations and drug delivery systems for traditional
therapeutics and psychedelic treatments, today announced a new
agreement with Sever Pharma Solutions for scale-up extrusion of the
Company’s SP-26 ketamine-loaded implant therapeutic targeting
fibromyalgia and chronic pain. In addition, Sever Pharma Solutions
will continue with analytical testing of the ketamine hydrochloride
(ketamine HCL) polymer implants using the optimal time-released,
dose-controlled formulation previously selected by Silo for
continuing pre-clinical studies.
“Sever Pharma Solutions has been our partner for
earlier production of the ketamine implants and validation of the
delivery system through successful assay testing,” said Silo
CEO Eric Weisblum. “We are pleased to continue our collaboration as
we move forward with further pre-clinical testing of our novel
non-opioid chronic pain therapeutic. This process is expected to
bring Silo closer to selecting the optimal final dosage and
formulation in SP-26 to be utilized in animal studies
If clinically successful, SP-26 could qualify for the FDA’s
streamlined 505(b)(2) regulatory pathway for drug approval.
About SP-26
Silo’s SP-26 is a ketamine-based injectable dissolvable polymer
implant for the treatment of chronic pain and fibromyalgia. The
subcutaneous implant is being designed to safely regulate dosage
and time release of the pain-relieving treatment.
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage
biopharmaceutical company developing novel therapeutics that
address underserved conditions including stress-induced psychiatric
disorders, chronic pain conditions, and central nervous system
(CNS) diseases. Silo focuses on developing traditional therapies
and psychedelic treatments in novel formulations and drug delivery
systems. The Company’s lead program, SPC-15, is an intranasal
treatment targeting PTSD and stress-induced anxiety disorders.
SP-26 is a time-release ketamine-loaded implant for fibromyalgia
and chronic pain relief. Silo’s two preclinical programs are
SPC-14, an intranasal compound for the treatment of Alzheimer’s
disease, and SPU-16, a CNS-homing peptide targeting multiple
sclerosis (MS). Silo’s research and development programs are
conducted through collaborations with universities and independent
laboratories. For more information,
visit www.silopharma.com and connect on social media
at LinkedIn , X , and Facebook .
Forward-Looking
Statements
This news release contains "forward-looking
statements" within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995. These
statements are identified by the use of words “could”, “believe”,
“anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”,
“predict”, “potential”, and similar expressions that are intended
to identify forward-looking statements. Such statements involve
known and unknown risks, uncertainties, and other factors that
could cause the actual results of Silo Pharma, Inc. (“Silo” or “the
Company”) to differ materially from the results expressed or
implied by such statements, including changes to anticipated
sources of revenues, future economic and competitive conditions,
difficulties in developing the Company’s technology platforms,
retaining and expanding the Company’s customer base, fluctuations
in consumer spending on the Company’s products and other factors.
Accordingly, although the Company believes that the expectations
reflected in such forward-looking statements are reasonable, there
can be no assurance that such expectations will prove to be
correct. The Company disclaims any obligations to publicly update
or release any revisions to the forward-looking information
contained in this presentation, whether as a result of new
information, future events, or otherwise, after the date of this
presentation or to reflect the occurrence of unanticipated events
except as required by law.
Contact
800-705-0120 investors@silopharma.com
Silo Pharma (NASDAQ:SILO)
過去 株価チャート
から 7 2024 まで 8 2024
Silo Pharma (NASDAQ:SILO)
過去 株価チャート
から 8 2023 まで 8 2024